PPC
GSK icon

Park Place Capital’s GSK GSK Stock Holding History

Park Place Capital’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121K Sell
2,185
-6,612
-75% -$358K 0.02% 238
2025
Q4 		$431K Sell
8,797
-1,527
-15% -$71.2K 0.09% 125
2025
Q3 		$446K Buy
10,324
+84
+0.8% +$3.28K 0.09% 130
2025
Q2 		$399K Buy
10,240
+8,144
+389% +$311K 0.09% 137
2025
Q1 		$81.2K Sell
2,096
-656
-24% -$24K 0.02% 284
2024
Q4 		$93.1K Sell
2,752
-122
-4% -$4.39K 0.03% 278
2024
Q3 		$117K Sell
2,874
-394
-12% -$16.1K 0.03% 270
2024
Q2 		$126K Sell
3,268
-1,286
-28% -$54.1K 0.04% 251
2024
Q1 		$195K Sell
4,554
-2,485
-35% -$102K 0.07% 236
2023
Q4 		$261K Sell
7,039
-939
-12% -$33.7K 0.1% 190
2023
Q3 		$289K Buy
7,978
+67
+0.8% +$2.38K 0.08% 191
2023
Q2 		$282K Sell
7,911
-441
-5% -$15.8K 0.08% 204
2023
Q1 		$297K Buy
8,352
+304
+4% +$10.6K 0.08% 199
2022
Q4 		$283K Buy
+8,048
New +$268K 0.08% 200

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Park Place Capital's GSK Position: Q1 2026 in Review

Park Place Capital reduced its GSK (GSK) stake by 75% in Q1 2026, selling an estimated $358K and leaving 2,185 shares worth $121K. The position accounts for 0.02% of the portfolio, ranked #238.

Park Place Capital first reported a position in GSK in Q4 2022 and has held it in 14 quarters since. The position peaked at $446K in Q3 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Park Place Capital held 2,185 shares of GSK worth $121K as of Q1 2026.
  • Park Place Capital sold 6,612 GSK shares in Q1 2026, an estimated $358K.
  • GSK made up 0.02% of Park Place Capital's portfolio in Q1 2026, its #238 holding.
  • Park Place Capital first reported a position in GSK in Q4 2022 and has held it in 14 quarters since.
  • Park Place Capital's GSK position peaked at $446K in Q3 2025.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Park Place Capital's 13F filing for Q1 2026, filed 9 Apr 2026.